TimeTeller puts our internal clocks at the center of personalized medicine

Your health treatments, especially for cancer, may soon be scheduled based on your personal biological rhythms, not just generic protocols.

German startup TimeTeller has developed a saliva test kit designed to measure an individual's circadian rhythm, aiming to personalize medicine by timing treatments to a patient's internal biological clock. CEO Angela Relógio, a physicist-engineer and molecular biologist, founded the company based on research indicating that treatment timing, not just the treatment itself, can significantly impact patient outcomes, particularly in oncology. While the direct-to-consumer kit currently offers advice on sleep, nutrition, and activity, the long-term goal is to refine cancer treatment protocols for better tolerance and effectiveness. TimeTeller has partnered with Techniker Krankenkasse, a major German health insurer, which is expanding reimbursement for the test to its 12 million members. The company is also exploring applications in metabolic and neurodegenerative diseases, with cancer remaining its primary focus.

TimeTeller's approach signals a broader shift toward chronomedicine, integrating biological timing into therapeutic strategies beyond traditional drug efficacy. This move has implications for how pharmaceutical companies develop and test drugs, potentially requiring new clinical trial designs that account for circadian variations. It also creates an opportunity for diagnostic companies to offer more sophisticated biomarkers tied to internal clocks, moving beyond simple genetic or proteomic profiling.

The company's focus on cancer as a core mission, supported by insurer reimbursement and academic partnerships, positions it to influence clinical practice in oncology. As TimeTeller refines its ability to tailor treatment schedules, patients could see reduced side effects and improved survival rates, making personalized timing a critical factor in cancer care alongside targeted therapies.